Antibody Binding to CHI3L1 for Treating Cancer
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Dec 5, 2024
app pub date -
Sep 30, 2022
filing date -
Sep 30, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
An antibody or an antigen-binding portion thereof binding to CHI3L1 includes a heavy chain variable region and a light chain variable region. The antibody or the antigen-binding portion thereof targeting CHI3L1 not just inhibit activated AKT and ERK signals, cancer cells migration, tumor progression, tumor fibrosis, angiogenesis and cancer-induced muscle loss such as cachexia, but modulate TME toward an immunostimulatory phenotype.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully